BioWorld Asia

Feb. 28, 2007

Two VC Companies Closing Funds Raising More than $1B

LONDON - Two European venture capital firms announced the closing of new funds, raising €785 million (US$1.03 billion) in total for investment in early stage companies. (BioWorld International) Read More

Algeta Reports Phase II Data For Alpharadin In Prostate Cancer

Gene Variant Halves Risks From A Number Of Infectious Diseases

European Patent On Enzymes Sends Ark Stock To High Point

Tighter Drug Safety Monitoring Rules Are Coming To Europe

Top Europe Research Seeks Clarity on Stem Cell Rules

Genfit Renews Collaborations With Sanofi-Aventis, Solvay

Hybrigenics Refocuses Its Efforts On Ubiquitin-Specific Proteases

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 9, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...